Genmab raises share capital via employee warrant exercise
Genmab A/S will issue 164,828 new shares after employees exercised warrants, generating about DKK 369.7 million for the company.
Genmab A/S announced on November 10, 2026 that its share capital will increase by 164,828 shares as a result of employee warrant exercises.1 The company noted that existing shareholders and others are not granted preemption rights in connection with this increase.1
The new shares were subscribed in cash at a series of prices per share with a nominal value of DKK 1, ranging from 2,961 shares at DKK 1,362.5 up to 1,078 shares at DKK 3,172, with intermediate tranches at various prices in between.1
Genmab said the transaction brings in proceeds of approximately DKK 369.7 million.1 The company stated that this issuance represents about 0.2641% of its total share capital.1
According to the filing, the new shares are ordinary shares with no special rights, are freely transferable, and carry dividend and other shareholder rights starting from the date of subscription.1 Genmab added that the shares will begin trading on Nasdaq Copenhagen once they are registered with the Danish Business Authority,1 and said it expects the capital increase to be completed shortly.1
Following the increase, Genmab reported that its total share capital will stand at DKK 62,570,683, consisting of 62,570,683 shares with a nominal value of DKK 1 each, representing the same number of voting rights.1
The announcement was filed with the U.S. Securities and Exchange Commission as part of a Form 6-K report for the month of November 2026, signed by Anthony Pagano, Genmab's Executive Vice President and Chief Financial Officer, on November 10, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.